{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-017380","form_type":"8-K","ticker":"ATYR","cik":"0001339970","company_name":"aTYR PHARMA INC","filed_at":"2022-08-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.464581+00:00","generated_at":"2026-06-23T23:45:28.180756+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"aTyr Pharma Q2 2022 cash $89.3M; initiates Phase 3 sarcoidosis study","bullets":["Cash, restricted cash, cash equivalents and investments $89.3M as of June 30, 2022.","R&D expenses $9.1M, G&A expenses $3.4M for Q2 2022; no revenue reported.","First sites initiated in global Phase 3 EFZO-FIT study for pulmonary sarcoidosis.","FDA Fast Track designation granted for efzofitimod in pulmonary sarcoidosis.","Company on track to enroll first patient in Q3 2022; 28.1M shares outstanding."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-017380","json":"https://secwatch.observer/filing/0000950170-22-017380.json","markdown":"https://secwatch.observer/filing/0000950170-22-017380.md","text":"https://secwatch.observer/filing/0000950170-22-017380.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1339970/000095017022017380/0000950170-22-017380-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1339970/000095017022017380/life-20220815.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T23:45:28.180756+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}